Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
- Development of innovative CTL therapy targeting EBV-associated lymphomas using proprietary ExacTcell technology
- Integration of AI technology (Tevogen.AI) to enhance peptide selection and target identification
- Advancement in preclinical research with ongoing confirmation studies
- Still in early preclinical phase with no immediate revenue potential
- Will require additional capital raising to execute business plan
- Faces significant regulatory and development hurdles before commercialization
Insights
Tevogen's EBV-targeted therapy advances with AI integration, but remains in early preclinical stage without clear timeline to clinical trials.
Tevogen's update reveals ongoing preclinical development of their EBV-targeted cytotoxic T lymphocyte (CTL) therapy for EBV-associated lymphomas. The company is currently in the computer-based peptide selection phase, with concurrent laboratory validation of CTL responses to these targets. While this represents forward movement, investors should recognize this program remains in early-stage preclinical development with no specified timeline for IND filing or clinical trials.
The integration of Tevogen.AI into their research process potentially accelerates target identification across the EBV genome, which could enhance their therapeutic precision. However, the press release provides no quantifiable metrics on this AI implementation's effectiveness or timeline advantages.
The company's proprietary ExacTcell™ technology offers potential manufacturing advantages through precision-engineered T cells with high specificity and scalability. This approach aligns with broader industry trends toward cell therapies with improved manufacturability and specificity.
From a competitive standpoint, EBV-associated lymphomas represent a significant but increasingly crowded therapeutic area. Several companies are developing various approaches to target EBV-positive malignancies, including antibody-drug conjugates, bispecific antibodies, and other cell therapies. Tevogen's announcement lacks detail on their specific differentiation or competitive advantages in this landscape beyond general statements about their platform.
The scientific rationale provided by their CSO emphasizes targeting EBV proteins involved in tumorigenesis, which represents a mechanistically sound approach. However, the release contains minimal technical details about their target selection criteria or preliminary efficacy data that would allow for assessment of clinical potential.
WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas.
Computer-based selection of EBV peptides is currently underway as part of Tevogen’s preparation for a potential clinical trial using EBV-specific CTLs manufactured using the Company’s proprietary ExacTcell™ technology. ExacTcell enables precision-engineered T cells with a high degree of specificity and scalability. In parallel, Tevogen’s R&D laboratory has initiated confirmation studies to validate CTL responses to the selected viral peptides.
Tevogen Bio’s scientific and clinical teams are working closely with Tevogen.AI, the Company’s artificial intelligence initiative, to co-develop an advanced peptide selection strategy. This collaboration aims to accelerate the identification of immunologically active targets across the EBV genome and further strengthen Tevogen’s therapeutic precision.
“The mechanisms behind EBV-induced tumorigenesis, which includes the disruption of cellular pathways and the promotion of malignant growth by EBV proteins, have become increasingly clear in recent years,” said Neal Flomenberg, MD, Chief Scientific Officer of Tevogen Bio. “Targeting these proteins with highly specific CTLs presents an exciting research frontier and the potential for meaningful therapeutic breakthroughs in EBV-driven cancers.”
Tevogen Bio will continue to share updates as the EBV research progresses through its preclinical evaluation phase.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is Tevogen Bio's (TVGN) new therapy development focused on?
How is Tevogen Bio using AI in their EBV therapy development?
What stage is Tevogen's EBV therapy currently in?
What is Tevogen's ExacTcell technology?
Who is leading the scientific development at Tevogen Bio?
